Group items matching

in title, tags, annotations or url

We invite you to join our complimentary 1-hour Pain Management Webinar, meticulously crafted to equip you and your team with essential strategies for understanding, addressing, and alleviating pain in your patients' lives. This webinar will delve into various topics, including the evolving role of pharmacists in pain management, the significance of timely intervention, and initiatives like Haleon's #ListenToPain campaign Pain is a universal experience, with nearly everyone encountering it at some point in their lives. Whether it's acute or chronic, pain can significantly diminish the quality of life and hinder daily activities. Understanding the multifaceted nature of pain is crucial in developing effective management strategies.

Join the fight against pain! Globally, 93% of people experience it annually, with 1 in 3 enduring daily suffering. However, our approach requires improvement. Introducing our Pain Management Webinar! In just 60 minutes, equip yourself with strategies to effectively combat pain. Here's what we'll cover: Pharmacists' Evolving Role: Moving beyond mere medication. Refining Pain Assessment: Quantifying patient discomfort accurately. #ListenToPain: Improving patient communication. Tailored for British pharmacists dealing with both acute and chronic pain. Seize this opportunity to make a real difference. Reserve your spot now for invaluable insights!

Join the battle against pain! Worldwide, 93% experience it annually, with 1 in 3 enduring daily agony. But our approach needs refinement. Introducing our Pain Management Webinar! In just 60 minutes, equip yourself with strategies to combat pain effectively. Here's what's covered: Pharmacists' Evolving Role: Moving beyond medication. Perfecting Pain Assessment: Quantifying patient discomfort. #ListenToPain: Enhancing patient communication. Tailored for British pharmacists addressing acute and chronic pain. Seize this opportunity to make a tangible difference. Reserve your spot now for invaluable insights!

Join the fight against pain! Globally, 93% face it yearly, with 1 in 3 enduring daily agony. But we're not fighting smart. Enter our Pain Management Webinar! In just an hour, gain tools to tackle pain head-on. Here's what's inside: Pharmacists' New Role: Beyond pills. Mastering Pain Assessment: Quantify patient pain. #ListenToPain: Better patient talks. Tailored for GB pharmacists handling acute and chronic pain. Don't miss this chance to make a real impact. Secure your spot now for invaluable insights!

Hey there, folks! Ever find yourself caught up in the throes of pain, wondering if there's a better way to handle it? You're not alone. In fact, according to recent stats, a whopping 93% of people worldwide grapple with pain annually. And get this: 1 in 3 folks deal with it every single day. Crazy, right? But here's the kicker: despite pain being such a prevalent issue, many folks aren't tackling it head-on. Yep, you heard that right. There's a whole lot of suffering going on, and not enough proactive pain management happening. So, what's the solution? Well, that's where our Pain Management Webinar swoops in to save the day! Picture this: an hour jam-packed with enlightening insights, carefully curated to arm you and your team with the tools needed to understand, manage, and ease pain in your patients' lives. Diving Deep: What's Inside the Webinar Alright, buckle up because we're about to dive into the juicy details of what this webinar has in store for you. 1. The Evolving Role of Pharmacists First up, we're shedding light on the evolving role of pharmacists in the realm of pain management. Yep, you heard that right. It's not just about doling out pills anymore. Pharmacists are becoming key players in the fight against pain, and we'll show you exactly how. 2. Decoding Pain Assessment Ever struggle to figure out just how much pain your patients are in? We feel you. That's why we're dedicating some time to decode the art of pain assessment. By the time you're done with this segment, you'll be a pro at understanding and quantifying your patients' pain levels. 3. #ListenToPain: A Campaign for Better Conversations And last but certainly not least, we're shining a spotlight on Haleon's #ListenToPain campaign. This bad boy is all about fostering better conversations between you and your patients. Trust us, folks, communication is key when it comes to pain management, and this campaign's got all the tools you need to nail those conversations. Tailored Jus

Amidst the pervasive prevalence of pain, with 93% of the global populace experiencing it annually and 1 in 3 enduring daily discomfort, there persists a reluctance to address and treat pain proactively. This leads to a heightened burden of suffering among individuals. Join us for an enlightening 1-hour Pain Management Webinar, meticulously crafted to equip you and your team with vital strategies to comprehend, manage, and alleviate pain in patients' daily lives. Delve into topics such as the pharmacist's evolving role, understanding pain assessment, and Haleon's #ListenToPain campaign, aimed at fostering better patient conversations. Tailored for pharmacists in GB dealing with acute or chronic pain, this webinar promises to enhance patient care and contribute positively to their well-being. Don't miss out on this opportunity to make a meaningful difference. Register now to secure your spot at this impactful event!

Amidst the pervasive prevalence of pain, with 93% of the global populace experiencing it annually and 1 in 3 enduring daily discomfort, there persists a reluctance to address and treat pain proactively. This leads to a heightened burden of suffering among individuals. Join us for an enlightening 1-hour Pain Management Webinar, meticulously crafted to equip you and your team with vital strategies to comprehend, manage, and alleviate pain in patients' daily lives. Delve into topics such as the pharmacist's evolving role, understanding pain assessment, and Haleon's #ListenToPain campaign, aimed at fostering better patient conversations. Tailored for pharmacists in GB dealing with acute or chronic pain, this webinar promises to enhance patient care and contribute positively to their well-being. Don't miss out on this opportunity to make a meaningful difference. Register now to secure your spot at this impactful event!

Over the last few years, we've seen the aftermath of Covid-19, with the demand for consumer health products being unprecedented and unpredictable, placing pressure on supply chains and labour market. In turn, the industry has experienced acute shortages across the healthcare sector, placing huge pressure on pharmacists, doctors, nurses, and other healthcare professionals. Europe has an estimated shortage of around 50,000 public-sector doctors[1], which is set to increase in the coming years. While this shortage stems from several complex problems, there is a hidden force that could play a key part in helping to alleviate this burden. That force is the potential of self-care. Encouragingly, last month the UK government recognised the unique role that self-care can play through the introduction of its Delivery plan for recovering access to primary care. Through this, it has pledged to empower patients to manage their own health through several commitments, including improving accessibility to online tools and reclassifying medicines to make formerly prescribed options available over the counter.

The National Institute for Health and Care Excellence (NICE) has released conclusive draft guidance, suggesting Pfizer's Vydura (rimegepant) as a choice for treating acute migraines in adults with or without aura. However, there is a caveat. This recommendation applies exclusively to individuals with a prior history of migraines, meeting one of the following criteria: At least 2 triptans were tried and they did not work well enough or Triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough. This drug was developed by the US-based Biohaven Pharmaceuticals, acquired by Pfizer in 2022, in an $11.6 billion deal. Nurtec ODT is the commercial name for the drug in the US, while the European Union approved the drug under the name Vydura in April 2022. NICE recommended rimegepant, an oral lyophilisate (dissolving wafer) and the first oral calcitonin gene-related peptide (CGRP) receptor antagonist for acute migraine treatment, to be taken at the onset of a migraine attack. Migraine affects one in seven people in the UK, often with a debilitating impact, Pfizer UK said in a statement. The condition entails symptoms such as head pain, vomiting, nausea, altered vision, fatigue, and heightened sensitivity to light, sound, and odours.

38th Annual Series Emergency Medicine & Acute Care Course is organized by The Center for Medical Education, Inc. from Jun 14 - 17, 2023 in New York City, USA.

People who use pharmacies in parts of Pendle have suffered shortages or delays in buying prescription medicines such as insulin, councillors have been told. In the Barnoldswick area, a number of pharmacies have been impacted and some councillors hope a new regional NHS organisation might look into the problems. However, pharmacies in the neighbouring town of Nelson are facing shortages with other medicines. A pharmacists in Nelson Pharmacy told Pharmacy Business that he was struggling to meet local demand for children's paracetamol due to ongoing shortages. Pendle Council's West Craven Area Committee heard about the issues at its latest local meeting, held in Earby. An agenda for the committee stated: "Pharmacy provision in West Craven. It is reported that there is an acute problem with people being unable to get prescriptions filled, with Whitworth chemists suffering a breakdown in service. Previously, Well chemists has suffered similar problems." Speaking at the meeting, Lib-Dem Coun David Whipp said: "It's quite an appalling situation where people are queuing 30 minutes to get a prescription filled but when they get to the counter they are told it's not ready. They have to go home and come back at 5pm. It's an ongoing problem. "It includes insulin, which is critical for people with diabetes. I know several people who have failed to get insulin, It's a very serious problem." He added: "I think the committee should contact the local integrated care service. I think they are responsible for primary care which includes pharmacies. We need to find out what's happening and improve things in future. "

New research has shown that chronic pain can be objectively measured using brain signals, a report in The Conversation said. According to the report, a team of researchers conducted a study using brain implants capable of recording neural signals over an extended period. Their aim was to identify reliable markers of chronic pain severity in four patients as they went about their daily lives. While pain is typically a subjective experience, there is still much to discover about how pain signals are processed in the brain. Previous studies often relied on artificial settings, and the relationship between acute and chronic pain circuits remained unclear. To investigate this further, the researchers surgically implanted electrodes in the brains of four patients experiencing post-stroke pain and phantom limb pain. Neural signals were recorded in specific brain regions associated with planning, expectation, and emotion. The patients were then asked to report their pain severity levels multiple times a day for up to six months. Machine learning models were developed to analyse the recorded brain activity signals and predict the patients' self-reported pain intensity scores.

Emergency Medicine & Acute Care 2023 Course will be able to effectively translate the strategies into improved diagnostics and implement a better treatment plan for their patients.

The Course is Designed for Healthcare Workers Who Are Looking Into the " Point of Care Ultrasound" to Improve the Management of Acute and Chronic Lung Disease. The lecture on Lung Ultrasound in Critical Care Medicine and Emergency is a lecture by Dr. Federico Conforto. 

The recruitment of pharmacists in Primary Care Networks (PCNs) has exacerbated a general shortage of pharmacists, revealed an independent review of Integrated Care Systems (ICSs) published on Tuesday (4 April). The review, Rt Hon Patricia Hewitt, highlighted the impact that the Additional Roles Reimbursement Scheme (ARRS) roles for pharmacists are having on the community pharmacy sector. "Contracts with national requirements can have unintended consequences when applied to particular circumstances. For instance, the national requirements and funding of Additional Roles Reimbursement Scheme (ARRS) roles for community pharmacists within PCNs, has on occasion exacerbated the problem of a general shortage of pharmacists, with some now preferring to work within primary care rather than remain in community pharmacies or acute hospitals, compounding the problem of community pharmacy closures and delayed discharges." It set out to consider the oversight and governance of ICS in England and the NHS targets and priorities for which Integrated Care Boards (ICBs) are accountable, including those set out in the Government's mandate to NHS England. As part of this work, Hewitt and her team engaged with a wide range of stakeholders representing various local health and social care settings, including LPCs.

The Pharmaceutical Society NI (PSNI)'s Council has decided to freeze the annual registration fee for the current financial year 2023/24. The annual registration fee is considered each year by the PSNI's council. At its meeting in November 2022, Council members in recognition of the effects of the Covid-19 pandemic, the personal and professional impact of the cost of living crisis on pharmacists, and the overall cost of regulation agreed to maintain registration fees at their current level for the next financial year. Pharmaceutical Society NI's Chief Executive Michaela McAleer said: "I am pleased with Council's decision to continue the freeze on registration fees for the 7th successive year. We are acutely aware of the pressures facing the pharmacy profession and hope this can provide some reassurance to the profession as we deal with these financially difficult times.

Jonathan Burton will receive the 2022 RPS Charter Award for his outstanding work for the Society and the wider profession in promoting the interests of pharmacy. The award will be presented by the President at a future meeting of Fellows and Members to take place at the Society's Edinburgh office on 22nd March 2023. Jonathan's main role is as a practising, patient-facing pharmacist within the community in NHS Forth Valley where he uses his advanced practice skills and independent prescribing qualification to assess and treat acute ENT, dermatology, and respiratory conditions. He was one of the first community pharmacist prescribers in Scotland and has always been at the forefront of innovation and service development. Jonathan has demonstrated outstanding commitment and passion for the pharmacy profession throughout his career. He has excelled as a pharmacist in the Right Medicine Pharmacy group, on local and national committees, in advocacy for the pharmacy profession and as a local and national leader who is highly regarded as an exceptional role model for the profession.

Sun Pharmaceutical Industries, India's largest drugmaker by revenue, reported a better-than-expected 5.2 per cent rise in third-quarter profit on Tuesday, driven by higher sales of its specialty drugs. The company, known for its consumer healthcare products such as Revital vitamins and pain relief medicine Volini, said it earned a consolidated net profit of 21.66 billion rupees ($265.23 million) in three months ended Dec. 31, up from 20.59 billion rupees last year. Analysts, on average, had expected the company to report a profit of 21.26 billion rupees, according to Refinitiv IBES data. Total revenue from operations climbed nearly 14 per cent to 112.41 billion rupees. Input costs rose 8.5 per cent. Drug sales in India rose 7.1 per cent to 33.92 billion rupees, whereas sales in the United States climbed 16.6 per cent to 34.66 billion rupees, with each of the two regions accounting for 31 per cent of the company's total consolidated sales. The company, founded in 1983, makes over-the-counter medications, anti-retrovirals and active pharmaceutical ingredients for chronic and acute treatments.

An executive director of Day Lewis and also board director and member of Association of Independent Multiple pharmacies (AIMp) Jay Patel highlighted the key issues and on ground challenges faced by the community pharmacies in a meeting hosted by Prime Minister Rishi Sunak and health secretary Steve Barclay in Downing Street on Saturday (January 7) to tackle the NHS pressure. In his interview with BBC, he said: "He (prime minister) was very engaging and trying to understand the key issues and practical challenges on the ground." Patel described the meeting atmosphere as 'collaborative and proactive', and said, "people were genuinely asked their options and there were listeners too." On BBC, answering to a question on 'how community pharmacies can alleviate the NHS pressure?', Patel said: "Pharmacies is the workplace for this. We have trust of our patients; we have high skilled workforce both clinically and professionally. One of the opportunities we have is working around the acute treat

Enterosgel is a versatile safe drug-free alternative to current anti-diarrhoeal medicines found on pharmacy shelves. Enterosgel is different from other anti-diarrhoeals within this category, as it is suitable for children aged one year and over, so can be taken by the whole family. This intestinal adsorbent can be used for both acute diarrhoea due to gastrointestinal infections and for chronic irritable bowel syndrome with diarrhoea (IBS-D). Why should community pharmacists stock this brand? Unlike anti-diarrhoeals which work by slowing gut motility, Enterosgel is an intestinal adsorbent which physically binds harmful substances from the gut, that can cause diarrhoea and other gastrointestinal symptoms and expels them naturally with the stools. Because it is a medical device not a medicine, has no pharmacological action and is not absorbed by the body, it is a safe option for children and adults and can help reduce the likelihood of side effects which can be an issue with anti-diarrhoeal medicines. Enterosgel has a unique composition of an adsorbent mineral gel based in water, it contains no additional preservatives or additives so is easy to recommend from vegetarians to people with allergies or intolerances. The gel is mixed with water and taken orally in between meals; it is tasteless so well tolerated even by children.